Construct: ORF TRCN0000465501
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF002965.1_s317c1
- Derived from:
- ccsbBroadEn_05939
- DNA Barcode:
- CTGAATGTTGTTTTAGAGTTACGA
- Epitope Tag:
- V5
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- CBLB (868)
Vector Information:
- Vector Backbone:
- pLX_317
- Pol II Cassette 1:
- SV40-PuroR
- Pol II Cassette 2:
- EF1a-TRCN0000465501
- Selection Marker:
- PuroR
- Visible Reporter:
- n/a
- Epitope Tag:
- V5
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321788.2 | 99.8% | 99.8% | (many diffs) |
| 2 | human | 868 | CBLB | Cbl proto-oncogene B | NM_170662.5 | 99.8% | 99.8% | (many diffs) |
| 3 | human | 868 | CBLB | Cbl proto-oncogene B | XM_011513257.1 | 99.8% | 99.8% | (many diffs) |
| 4 | human | 868 | CBLB | Cbl proto-oncogene B | XM_017007395.1 | 97.6% | 97.7% | (many diffs) |
| 5 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321786.1 | 97% | 97.1% | (many diffs) |
| 6 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321791.2 | 95.3% | 95.4% | (many diffs) |
| 7 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321793.2 | 95.3% | 95.4% | (many diffs) |
| 8 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321794.2 | 94.8% | 94.9% | (many diffs) |
| 9 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321795.2 | 94.8% | 94.9% | (many diffs) |
| 10 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321796.2 | 94.8% | 94.9% | (many diffs) |
| 11 | human | 868 | CBLB | Cbl proto-oncogene B | XM_017007399.1 | 94.8% | 94.9% | (many diffs) |
| 12 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321790.2 | 93.2% | 93.3% | (many diffs) |
| 13 | human | 868 | CBLB | Cbl proto-oncogene B | XM_017007398.1 | 92.7% | 92.8% | (many diffs) |
| 14 | human | 868 | CBLB | Cbl proto-oncogene B | XM_017007396.1 | 92.7% | 92.7% | (many diffs) |
| 15 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321789.1 | 92.2% | 92.2% | (many diffs) |
| 16 | human | 868 | CBLB | Cbl proto-oncogene B | XM_017007397.1 | 92.2% | 92.2% | (many diffs) |
| 17 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321797.2 | 90.3% | 90.4% | (many diffs) |
| 18 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321798.2 | 90.3% | 90.4% | (many diffs) |
| 19 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321799.2 | 90.3% | 90.4% | (many diffs) |
| 20 | human | 868 | CBLB | Cbl proto-oncogene B | XM_017007400.1 | 87.8% | 87.9% | (many diffs) |
| 21 | human | 868 | CBLB | Cbl proto-oncogene B | XM_011513259.3 | 85.3% | 84.5% | (many diffs) |
| 22 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321806.2 | 73.3% | 73.4% | (many diffs) |
| 23 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321807.2 | 73.3% | 73.4% | (many diffs) |
| 24 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321808.2 | 68.9% | 68.9% | (many diffs) |
| 25 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321811.2 | 68.3% | 68.4% | (many diffs) |
| 26 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321813.1 | 68.3% | 68.4% | (many diffs) |
| 27 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321816.2 | 63.9% | 63.9% | (many diffs) |
| 28 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321822.2 | 54.7% | 54.7% | (many diffs) |
| 29 | human | 868 | CBLB | Cbl proto-oncogene B | NM_001321820.2 | 54.6% | 54.5% | (many diffs) |
| 30 | human | 868 | CBLB | Cbl proto-oncogene B | NR_135811.2 | 44.6% | (many diffs) | |
| 31 | human | 868 | CBLB | Cbl proto-oncogene B | NR_135810.2 | 44% | (many diffs) | |
| 32 | human | 868 | CBLB | Cbl proto-oncogene B | XR_001740339.1 | 43.5% | (many diffs) | |
| 33 | human | 868 | CBLB | Cbl proto-oncogene B | XR_001740338.1 | 43.5% | (many diffs) | |
| 34 | human | 868 | CBLB | Cbl proto-oncogene B | NR_135808.2 | 43.4% | (many diffs) | |
| 35 | human | 868 | CBLB | Cbl proto-oncogene B | NR_135807.2 | 43.1% | (many diffs) | |
| 36 | human | 868 | CBLB | Cbl proto-oncogene B | NR_135812.1 | 42.4% | (many diffs) | |
| 37 | human | 868 | CBLB | Cbl proto-oncogene B | NR_135806.2 | 42.1% | (many diffs) | |
| 38 | human | 868 | CBLB | Cbl proto-oncogene B | NR_135809.2 | 40.9% | (many diffs) | |
| 39 | mouse | 208650 | Cblb | Casitas B-lineage lymphoma b | XM_006521947.1 | 88% | 95% | (many diffs) |
| 40 | mouse | 208650 | Cblb | Casitas B-lineage lymphoma b | XM_006521948.1 | 88% | 95% | (many diffs) |
| 41 | mouse | 208650 | Cblb | Casitas B-lineage lymphoma b | XM_006521949.1 | 88% | 95% | (many diffs) |
| 42 | mouse | 208650 | Cblb | Casitas B-lineage lymphoma b | XM_006521950.2 | 88% | 95% | (many diffs) |
| 43 | mouse | 208650 | Cblb | Casitas B-lineage lymphoma b | NM_001033238.1 | 84.2% | 91.1% | (many diffs) |
| 44 | mouse | 208650 | Cblb | Casitas B-lineage lymphoma b | XM_006521951.1 | 84.2% | 91.1% | (many diffs) |
| 45 | mouse | 208650 | Cblb | Casitas B-lineage lymphoma b | XM_006521952.3 | 74.1% | 79.5% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 66
- ORF end:
- 3012
- ORF length:
- 2946
- Sequence:
-
1 tcttccattt caggtgtcgt gaggctagca tcgattgatc aacaagtttg tacaaaaaag 61 ttggcatggc aaactcaatg aatggcagaa accctggtgg tcgaggagga aatccccgaa 121 aaggtcgaat tttgggtatt attgatgcta ttcaggatgc agttggaccc cctaagcaag 181 ctgccgcaga tcgcaggacc gtggagaaga cttggaagct catggacaaa gtggtaagac 241 tgtgccaaaa tcccaaactt cagttgaaaa atagcccacc atatatactt gatattttgc 301 ctgatacata tcagcattta cgacttatat tgagtaaata tgatgacaac cagaaacttg 361 cccaactcag tgagaatgag tactttaaaa tctacattga tagccttatg aaaaagtcaa 421 aacgggcaat aagactcttt aaagaaggca aggagagaat gtatgaagaa cagtcacagg 481 acagacgaaa tctcacaaaa ctgtccctta tcttcagtca catgctggca gaaatcaaag 541 caatctttcc caatggtcaa ttccagggag ataactttcg tatcacaaaa gcagatgctg 601 ctgaattctg gagaaagttt tttggagaca aaactatcgt accatggaaa gtattcagac 661 agtgccttca tgaggtccac cagattagct ctggcctgga agcaatggct ctaaaatcaa 721 caattgattt aacttgcaat gattacattt cagtttttga atttgatatt tttaccaggc 781 tgtttcagcc ttggggctct attttgcgga attggaattt cttagctgtg acacatccag 841 gttacatggc atttctcaca tatgatgaag ttaaagcacg actacagaaa tatagcacca 901 aacccggaag ctatattttc cggttaagtt gcactcgatt gggacagtgg gccattggct 961 atgtgactgg ggatgggaat atcttacaga ccatacctca taacaagccc ttatttcaag 1021 ccctgattga tggcagcagg gaaggatttt atctttatcc tgatgggagg agttataatc 1081 ctgatttaac tggattatgt gaacctacac ctcatgacca tataaaagtt acacaggaac 1141 aatatgaatt atattgtgaa atgggctcca cttttcagct ctgtaagatt tgtgcagaga 1201 atgacaaaga tgtcaagatt gagccttgtg ggcatttgat gtgcacctct tgccttacgg 1261 catggcagga gtcggatggt cagggctgcc ctttctgtcg ttgtgaaata aaaggaactg 1321 agcccataat cgtggatccc tttgatccaa gagatgaagg ctccaggtgt tgcagcatca 1381 ttgacccctt tggcatgccg atgctcgact tggacgacga tgatgatcgt gaggagtcct 1441 tgatgatgaa tcggttggca aacgtccgaa agtgcactga caggcagaac tcaccagtca 1501 catcaccagg atcctctccc cttgcccaga gaagaaagcc acagcctgac ccactccaga 1561 tcccacatct aagcctgcca cccgtgcctc ctcgcctgga tctaattcag aaaggcatag 1621 ttagatctcc ctgtggcagc ccaacgggtt caccaaagtc ttctccttgc atggtgagaa 1681 aacaagataa accactccca gcaccacctc ctcccttaag agatcctcct ccaccgccac 1741 ctgaaagacc tccaccaatc ccaccagaca atagactgag tagacacatc catcatgtgg 1801 aaagcgtgcc ttccaaagac ccgccaatgc ctcttgaagc atggtgccct cgggatgtgt 1861 ttgggactaa tcagcttgtg ggatgtcgac tcctagggga gggctctcca aaacctggaa 1921 tcacagcgag ttcaaatgtc aatggaaggc acagtagagt gggctctgac ccagtgctta 1981 tgcggaaaca cagacgccat gatttgcctt tagaaggagc taaggtcttt tccaatggtc 2041 accttggaag tgaagaatat gatgttcctc cccggctttc tcctcctcct ccagttacca 2101 ccctcctccc tagcataaag tgtactggtc cgttagcaaa ttctctttca gagaaaacaa 2161 gagacccagt agaggaagat gatgatgaat acaagattcc ttcatcccac cctgtttccc 2221 tgaattcaca accatctcat tgtcataatg taaaacctcc tgttcggtct tgtgataatg 2281 gtcactgtat gctgaatgga acacatggtc catcttcaga gaagaaatca aacatccctg 2341 acttaagcat atatttaaag ggagatgttt ttgattcagc ctctgatccc gtgccattac 2401 cacctgccag gcctccaact cgggacaatc caaagcatgg ttcttcactc aacaggacgc 2461 cctctgatta tgatcttctc atccctccat taggtgaaga tgcttttgat gccctccctc 2521 catctctccc acctccccca cctcctgcaa ggcatagtct cattgaacat tcaaaacctc 2581 ctggctccag tagccggcca tcctcaggac aggatctttt tcttcttcct tcagatccct 2641 ttgttgatct agcaagtggc caagttcctt tgcctcccgc tagaaggtta ccaggtgaaa 2701 atgtcaaaac taacagaaca tcacaggact atgatcagct tccttcatgt tcagatggtt 2761 cacaggcacc agccagaccc cctaaaccac gaccgcgcag gactgcacca gaaattcacc 2821 acagaaaacc ccatgggcct gaggcggcat tggaaaatgt cgatgcaaaa attgcaaaac 2881 tcatgggaga gggttatgcc tttgaagagg tgaagagagc cttagagata gcccagaata 2941 atgtcgaagt tgcccggagc atcctccgag aatttgcctt ccctcctcca gtatccccac 3001 gtcTAAATCT ATACCCAACT TTCTTGTACA AAGTGGTTGA TATCGGTAAG CCTATCCCTA 3061 ACCCTCTCCT CGGTCTCGAT TCTACGTAGT AATGAACTAG CCCGTAACTT GAAAGTATTT 3121 CGATTTCTTG GCTTTATATA TCTTGTGGAA AGGACGACTG AATGTTGTTT TAGAGTTACG 3181 AACGCGTTAA GTCgacaatc aacctctgga ttacaaaatt tgtgaaagat t